Watertown-based Tetraphase Pharmaceuticals Raises $10 Million in Second Round

From New England Tech Wire



Watertown, Mass. - Tetraphase Pharmaceuticals, a Watertown-based
developer of synthetic chemistry technology for drug discovery and development,
has raised $10 million in its second round of venture capital. Investors in the
deal include Mediphase Venture Partners, CMEA Ventures, Fidelity
Biosciences, Flagship Ventures and Skyline Ventures. Founded in
2006, Tetraphase Pharmaceuticals is capitalizing on technology based on a
process developed by organic chemist Andrew Myers of Harvard University. The advance
in chemistry provides the company with a range of commercial opportunities
across a number of significant disease categories, according to Tetraphase.

http://www.businesswire.com/news/home/20091006005955/en

http://www.tphase.com

View Tphase jobs now!